CETP

Obicetrapib (AMG-899) 是胆固醇酯转移蛋白的抑制剂。

Dalcetrapib (RO4607381) 是rhCETP 抑制剂(IC50:0.2 μM)，具有增加血浆中HDL 胆固醇含量的作用。

Evacetrapib (LY2484595) 是 CETP 的选择性抑制剂，在人血浆中，抑制人重组 CETP 蛋白 (IC50:5.5 nM) 和 CETP (IC50:36 nM) 活性。

是胆固醇酯转移蛋白 (CETP) 选择性抑制剂。根据人血浆的抑制曲线，Torcetrapib (CP-529414) 对CETP 的最有效浓度为 37 nM。

Anacetrapib (MK-0859) 是 CETP 的抑制剂，能够抑制 rhCETP (IC50:7.9±2.5 nM) 和 C13S CETP 突变型 (IC50:11.8±1.9 nM) 的活性。

20-HC-Me-Pyrrolidine是一种有效的Aster蛋白抑制剂，对 Aster-A、Aster-B 和 Aster-C 的 IC50=0.06~0.71 μm，能够阻断Aster蛋白结合和转移胆固醇的能力，包括抑制LDL胆固醇向内质网的移动。

CETP-IN-3 is an inhibitor of the plasma glycoprotein cholesterol ester transfer protein (CETP), elevating HDL-C through inhibition of CETP.

CETP-IN-4 is a cholesteryl ester transfer protein (CETP) inhibitor.

Erabulenol A 是一种胆固醇酯转移蛋白（CETP）抑制剂，可从 Penicillum sp. 中提取获得。

CKD-519 is a selective inhibitor of cholesteryl ester transfer protein (CETP). It inhibits CETP-mediated transfer of cholesteryl ester in human serum (IC50: 2.3 nM).

Potent cholesteryl ester transfer protein (CETP) inhibitor (IC50 = 4 nM in an enzyme-based scintillation proximity assay). Inhibits cholesteryl ester transfer and increases HDL-C levels in vivo. Orally bioavailable. Qiao et al (2015) Triphenylethanamine derivatives as cholesteryl ester transfer protein inhibitors: discovery of N-[(1R)-1-(3-cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamid J.Med.Chem. 58 9010 PMID:26524347

Rosenonolactone exhibits inhibitory activity against prolyl endopeptidase and thrombin.

TAP311 is an inhibitor of cholesteryl ester transfer protein (CETP)(IC50 of 62 nM).

CP-532623, a close structural analog of Torcetrapib, is a CETP inhibitor with highly lipophilic properties. It elevates high-density lipoprotein cholesterol.

CP 524515 是一种胆固醇酯转移蛋白 (CETP) 的有效抑制剂，能够增加高密度脂蛋白胆固醇水平。

Implitapide is an inhibitor of microsomal triglyceride transfer protein (MTP).

MK-8262, an orally active and potent cholesteryl ester transfer protein (CETP) inhibitor (IC 50 = 53 nM, log D = 5.3), is a bistrifluoromethyl analogue that shows promise in research related to high-density lipoprotein (HDL) and low-density lipoprotein (LDL) with potential implications for coronary heart disease (CHD).